Home | Regulatory Tracker | Retatrutide
Retatrutide
Investigational — not approved
as of October 2026
By Stephen Kimball, 26+ years researching the health, wellness, supplement, and peptide industries
As of October 2026, retatrutide is still in clinical trials. It isn’t approved for any use, it isn’t part of any approved drug, and FDA says pharmacies can’t legally compound it. That means there’s no prescription route to it outside a clinical trial. Anything sold online as retatrutide is coming from the unregulated “research use only” market, and FDA has warned companies selling it that way.
Sources
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss ("Retatrutide cannot be used in compounding")
U.S. Food & Drug Administration
dated Oct 2026
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials
Eli Lilly and Company
dated Jul 2026
Change log
May 2026
Lilly reports first Phase 3 (TRIUMPH-1) results.
July 2026
Lilly reports two more positive Phase 3 trials and says it plans a U.S. submission in Q1 2027.
October 2026
FDA’s GLP-1 page states retatrutide cannot be used in compounding.